Form 8-K - Current report:
SEC Accession No. 0001437749-22-026959
Filing Date
2022-11-10
Accepted
2022-11-10 17:00:59
Documents
13
Period of Report
2022-11-10
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20221110_8k.htm   iXBRL 8-K 33762
  Complete submission text file 0001437749-22-026959.txt   166037

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dffn-20221110.xsd EX-101.SCH 3602
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20221110_def.xml EX-101.DEF 11533
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20221110_lab.xml EX-101.LAB 15415
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20221110_pre.xml EX-101.PRE 11689
7 EXTRACTED XBRL INSTANCE DOCUMENT dffn20221110_8k_htm.xml XML 2578
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 221378295
SIC: 2834 Pharmaceutical Preparations